TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of DWJ1248 in Patients With Mild to Moderate COVID-19 Compared to the Placebo

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adults over the age of 19 as of the signed date in written consent~* Subjects with mild or moderate COVID-19 according to RT-PCR test (Total score of NEWS is 0-6 or if one item is 3 points)~* Subjects who have symptoms within 7 days or 72 hours after diagnosis~Exclusion Criteria:~* Subjects who cannot orally administer the investigational products~* Subjects who need administration of immunosuppressants~* Subjects who are allergic or sensitive to investigational products or its ingredients~* Subjects who have a history of drug and/or alcohol abuse within 52 weeks before screening~* Subjects who have been identified with uncontrolled concomitant diseases or conditions, including significant mental illness and social conditions, that may affect compliance with clinical trial procedures according to the determination of the investigators

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- DWJ1248 (Type: EXPERIMENTAL): Camostat mesylate
- Placebo (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Bifocal Right Ventricular PAcing in Right Bundle Branch blocK and Heart Failure With Reduced Ejection Fraction. The Study Tests the Superiority of Right Ventricular Bifocal Stimulation Over VVI Implantable Defibrillator in Right Bundle Branch Block and Heart Failure.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with RBBB and HFrEF (defined by left ventricular ejection fraction ≤35%) in sinus rhythm, who remain in NYHA class II-III or ambulatory NYHA class IV despite OMT.~Exclusion Criteria:~* Refusal or withdrawal of informed consent.~* Renal failure (defined by an estimated glomerular filtration rate ≤ 60 ml/min)~* Life expectancy \< 12 months~* Active neoplasm~* Permanent atrial fibrillation~* 40 days following acute coronary syndrome~* Atrio-ventricular block (from second degree AV block)~* Valvular heart disease with surgery indications

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Bifocal stimulation (Type: ACTIVE_COMPARATOR): Active comparator is represented by programming bifocal stimulation (bifocal DDD mode). Every patients will undergo crossover randomization (from bifocal DDD mode to VVI and vice versa).
- VVI 40 (Type: PLACEBO_COMPARATOR): Placebo comparator is represented by programming the device in VVI mode 40/mins. Every patients will undergo crossover randomization (from VVI to bifocal DDD mode and vice versa).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The St. Marys and The Mater Switch Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* HIV-1 infected males or females~* Between 18 and 65 years of age~* Signed informed consent~* Currently receiving a stable antiretroviral regimen comprising of:~  * two licensed NRTIs including abacavir and/or didanosine~ * any licensed boosted protease inhibitor at any dose (excluding tipranavir\*)~* Undetectable plasma HIV RNA to less than 50 copies/mL for at least 24 weeks prior to screening~* Availability of stored plasma with which to perform a tropism assay~* CCR5 tropic HIV virus based on a tropism assay from a stored plasma sample~* Willing to continue unchanged, or to modify antiretroviral therapy, in accordance with the randomisation assignment~* No documented viral resistance to currently licensed HIV-1 protease inhibitors based either on previous HIV-1 genotypic resistance testing or in the judgement of the study investigators~* No previous exposure to maraviroc or CCR5 receptor antagonists~* Subjects in good health upon medical history, physical exam, and laboratory testing in the opinion of the investigator~* Female subjects who are heterosexually active and of childbearing potential (i.e., not surgically sterile or at least two years post menopausal) must avoid becoming pregnancy as follows from screening through completion of the study using one or both of the following methods:~  * barrier contraceptives (condom, diaphragm with spermicide)~ * IUD PLUS a barrier contraceptive~* Female subjects of childbearing potential must have a negative pregnancy test~Exclusion Criteria:~* failure of current antiretroviral regimen due to virological failure~* active opportunistic infection, malignancy or significant co-morbidities in the opinion of the investigator~* pregnancy~* current prohibited concomitant medication (as listed in section 4.1.4)~* no available stored plasma sample predating their current antiretroviral regimen upon which a tropism assay can be performed~* active HBV infection as evidenced by positive hepatitis B surface antigen~* active hepatitis C virus infection as evidenced by positive HCV PCR or HCV antibody.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Immediate switch (Type: EXPERIMENTAL): * Continue current boosted protease inhibitor~* Switch NRTI backbone to maraviroc 150 mg bid
- Continue current antiretroviral therapy (Type: ACTIVE_COMPARATOR): * Continue current antiretroviral regimen until week 12 then switch therapy as per arm 1.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: HIV - Monotherapy in Switzerland (MOST-ch)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age \> 18 years.~* HIV seropositive.~* HAART (\> 6 months) with at least 3 months successfully suppressed HIV- RNA (two most recent RNA measurements \< 50 cp/ml). HAART is defined as either:~  * 1 PI plus 2 NRTIs,~ * 1 NNRTI plus 2 NRTIs, or~ * 3 NRTIs.~* HIV-RNA in plasma \< 50 cp/ml at screening.~* Stable antiretroviral therapy (unchanged drug combination) during the last four weeks.~* If not currently on a LPV/ r based therapy, willing to switch to LPV/ r bid therapy in case patient is randomized to the monotherapy arm~* Signed written informed consent.~* Highly motivated patients able to understand the investigational nature of this open observational study and willing to participate in additional procedures.~Exclusion Criteria:~* Other investigational substance or substances active against HIV.~* Previous history of adverse events with the drugs under investigation.~* Previous history of any virological treatment failure (does not include deliberate treatment interruption) or documented resistance against the drugs under investigation (LPV/r).~* Patient who has no effective alternative treatment options in case the study treatment fails (according to the physician's judgment).~* Pregnancy (negative pregnancy test for women of childbearing potential at screening).~* Active AIDS-defining disease necessitating antibiotic or chemotherapy at the time of screening.~* Chronic hepatitis B.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Monotherapy (Type: EXPERIMENTAL): Ritonavir-boosted lopinavir (Kaletra®) will be used as monotherapy
- Continued ART (Type: ACTIVE_COMPARATOR): Continuation Therapy, conventional triple HAART

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Study to Compare the Efficacy and Safety of Micafungin Versus Conventional Amphotericin B for the Treatment of Neonatal Candidiasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Infant greater than 48 hours of life after birth up to day of life 120 at the time of culture acquisition~* Diagnosis of proven invasive candidiasis within 4 days prior to study start~* Subject's parent or legal guardian agrees not to allow subject to participate in another study with another investigational drug while on treatment.~Exclusion Criteria:~* Infant with any history of a hypersensitivity or severe vasomotor reaction to any echinocandin or systemic amphotericin B product~* Infant who has received more than 48 hours of systemic antifungal therapy prior to the first dose of study drug~* Infant who has a breakthrough systemic fungal infection while receiving amphotericin B product or an echinocandin as prophylaxis~* Infant who has failed prior systemic antifungal therapy for this episode of invasive candidiasis~* Infant who is co-infected with a non-Candida fungal organism~* Infant whose positive yeast cultures are solely from an indwelling bladder catheter (unless obtained at the time the indwelling catheter was placed) or sputum.~* Infant previously enrolled in this study

- Gender: ALL
- Minimum Age: 48 Hours
- Maximum Age: 120 Days
- Healthy Volunteers: f

Study Arms:
- Micafungin (Type: EXPERIMENTAL): Infants received micafungin at a dose of 10 mg/kg per day by intravenous infusion for a minimum of 21 days to a maximum of 28 days for infants without end-organ dissemination or for a maximum of 42 days for infants with end-organ dissemination.
- Amphotericin B deoxycholate (Type: ACTIVE_COMPARATOR): Infants received amphotericin B deoxycholate (CAB) at a dose of 1.0 mg/kg per day by intravenous infusion for a minimum of 21 days to a maximum of 28 days for infants without end-organ dissemination or for a maximum of 42 days for infants with end-organ dissemination.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Registrational Trial to Compare Effectiveness of Two Digital Software Medical Devices as Adjunctive Oncology Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Stage I-III breast cancer or Stage I-III NSCLC who are currently in active treatment or have completed initial cancer directed treatments (surgery, radiation, chemotherapy) within the past 3 months;~* Are experiencing at least moderate anxiety (GAD-7 \>10) or mild-to-moderate depression (PHQ-8 score 5-11);~* Are fluent in English; and~* Have access to smartphone, or tablet capable of running iOS or Android software.~Exclusion Criteria:~* Previous history of cancer;~* \<2-yr survival prognosis as determined by treating clinician;~* Currently participating in investigative CBT trial for treatment of anxiety or depression;~* Participant is unable to complete training, has cognitive deficits, more severe psychiatric conditions, lack of access to internet accessible device or psycho-social conditions (e.g., other social conditions, that would interfere with adherence to self-directed care), such that in investigator's opinion the participant would be unable to complete the study;~* Recently completed use of Blue Note Therapeutics Covid Cancer Care Program or other Blue Note Therapeutics-sponsored study; and~* PHQ-9 Q9 response \>0 AND Columbia Suicide Severity Risk Scale (or equivalent) score of Category 2- suicidal ideation at screening.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Attune™ (Type: ACTIVE_COMPARATOR): Attune™ is a completely digital, 10-session, cognitive behavioral therapeutic intervention.
- Cerena™ (Type: ACTIVE_COMPARATOR): Cerena™ is a completely digital, 10-session, health education and wellness intervention.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Homeopathy for Moderate Depression (Acute Phase)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* diagnosis of major depression by a psychiatrist,~* patients must not be currently taking antidepressants or anxiolytic drugs (with the exception of Lorazepam as rescue medication, maximal dose 1.5 mg/day)~* Capability and willingness to give informed consent and to comply with the study procedures will also be required~Exclusion Criteria:~* current mild episode of depression (HAM-D \< 17)~* current severe episode of depression (HAM-D \> 24)~* schizophrenia or other psychotic disorders~* bipolar affective disorder~* schizoaffective disorders~* alcohol or other substance abuse~* eating disorders~* a clinically significant (Diagnostic and Statistical Manual of Mental Disorders)-Axis II disorder~* severe depression, which previously motivated a suicide attempt~* a score of 4 or 5 in the Columbia-Suicide Severity Rating Scale (C-SSRS)up to three months before screening;~* a clinically significant acute or chronic disease that would hinder regular participation in the study~* treatment with antipsychotics, antidepressants, sedatives/hypnotics or mood stabilizers four weeks prior to the screening~* complementary or alternative treatment simultaneously to the study (for example, acupuncture, phytotherapy, etc.)~* homeopathic treatment eight weeks prior to study entry~* psychotherapy~* simultaneous participation in another clinical trial (the last participation in a previous clinical trial must be completed at least three months prior to screening)~* concomitant pregnancy or breastfeeding~* patients who are assumed to have a linguistic, intellectual or any other reason for not understanding the meaning of the clinical trial and for not complying with the necessary study procedures~* persons who have been institutionalized by a court order~* patients with an application for a pension

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Group 1 (Type: EXPERIMENTAL): None
- Group 2 (Type: EXPERIMENTAL): None
- Group 3 (Type: EXPERIMENTAL): None
- Group 4 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Non-invasive Evaluation of Portal Pressure by MRI

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Suspicion of chronic liver disease~* Indication to perform a liver biopsy transjugular~* Patient able to consent~Exclusion Criteria:~* contraindication to MRI:~* Holders of a pacemaker or a defibrillator, an implanted material activated by electrical, magnetic or mechanical~* Holders of hemostatic clips intracerebral aneurysms or carotid arteries, bearing orthopedic implants~* claustrophobic~* Severe hepatic encephalopathy~* Inability to MRI in the week surrounding the first jugular

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intervention (Type: EXPERIMENTAL): The measurement of portosystemic pressure gradient will be performed before liver biopsy.~Then liver biopsy is performed. The MRI was performed on the day of biopsy or within one week around the completion of the biopsy.~The MRI machine used is the Siemens 3T.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Trials to Assess Safety and Efficacy of DWRX2003 Combination With Remdesivir in Moderate to Severe COVID-19 Patients.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18 years at time of signing the Informed Consent Form (ICF).~* SARS-CoV-2 infection documented by RT-PCR within 7 days prior to randomization.~* Hospitalized patients who meet the criteria of moderate or severe COVID-19.~* Patients who are not pregnant, based on urine pregnancy test during screening, and randomization.~* Female patients of childbearing potential practice effective contraception during the study and be willing and able to continue contraception for 60 days after their dose of study treatment.~* Male patient and/or Female patient's partner agree to use condoms or should have undergone vasectomy or spermicide in addition to female contraception for additional protection against conception for 60 days after their dose of study treatment.~* Patients who are anticipated to available for the entire study period and is capable of understanding and communicating with the investigators and clinical study facility staff.~* Patients who agree to give written informed consent and are willing to participate in the study.~Exclusion Criteria:~* Patients with BMI ≥30 and/or body weight \< 40kg~* Patients receiving or who have received antiviral therapy and antiretroviral therapy within 28 days prior to the screening visit.~* Patients who cannot be administered intramuscularly to bilateral ventro-gluteal area.~* Patients with uncontrolled respiratory disease other than COVID-19 pneumonia (i.e. COPD, asthma, cystic fibrosis, etc.)~* Patients who have active malignancy, history of active malignancy or chemotherapy within 1 year from the screening.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Niclosamide 432mg (Type: EXPERIMENTAL): Niclosamide 432mg (intramuscular injection) + Remdesivir
- Niclosamide 960mg (Type: EXPERIMENTAL): Niclosamide 960mg (intramuscular injection) + Remdesivir
- Placebo (Type: PLACEBO_COMPARATOR): Placebo (intramuscular injection) + Remdesivir

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Dual Energy CT: A New Method for Better Dose Calculation in Proton Beam Therapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: OTHER
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Cancer patients who are scheduled for a control CT scan~Exclusion Criteria:~* Under 18 years of age

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Pre-op Paravertebral Blocks to Decrease Post-op Pain Following Mastectomy With Immediate Tissue Expander (TE) Reconstruction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Be Female aged 18-100 years.~* Choose mastectomy followed by bilateral immediate tissue expander breast reconstruction.~* Have no inflammatory breast cancers.~* Be aware of the nature of her malignancy.~* Understand the study purpose, requirements, and risks.~* Be able and willing to give informed consent.~Exclusion Criteria:~* Any concurrent opioid analgesic use (baseline opioid use must be 0 to be eligible).~* Liver dysfunction and/ or cirrhosis.~* Renal insufficiency, with creatinine greater than 1.5 mg/mL.~* Patients weighing less than 50 Kg.~* Concurrent use of the SSRI antidepressant fluvoxamine (Luvox).

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ropivacaine Group (Type: EXPERIMENTAL): Paravertebral block injections of study solution will occur using the landmark-based classic technique with a 22-gauge Tuohy needle to deliver 0.5% ropivacaine (up to 0.8 mL/kg, equivalent to 4mg/kg).
- Saline Group (Type: PLACEBO_COMPARATOR): Paravertebral block injections of normal saline (up to 0.8 mL/kg) will occur using the landmark-based classic technique with a 22-gauge Tuohy needle. Immediately after completion of the injections, patients will be repositioned supine and general anesthesia induced in the standard manner.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues